Hepatic progenitor cells and uses thereof

• US 8,415,149 B2
• Filed: 05/06/2010
• Issued: 04/09/2013
• Est. Priority Date: 05/06/2010
• Status: Active Grant

• Current Assignee: Gwo Xi Stem Cell Applied Technology Co., Ltd.
• Original Assignee: Gwo Xi Stem Cell Applied Technology Co., Ltd.
• Inventors: Harn, Horng-Jyh, Lin, Shinn-Zong
• Primary Examiner(s): DAVIS, RUTH A
• Application Number:
  US12/774,776
• Publication Number:
  US 20110274664A1
• Time in Patent Office: 1,069 Days
• Field of Search: 435/325, 435/363, 435/370, 435/372, 424/583
• US Class Current: 435/325
• CPC Class Codes: A61K 35/407 Liver; Hepatocytes
• CPC Class Codes: A61K 35/545 Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: C12N 2502/14 hepatocytes
• CPC Class Codes: C12N 2506/025 from extra-embryonic cells, e.g. trophoblast, placenta
• CPC Class Codes: C12N 5/067 Hepatocytes

Abstract

Disclosed are cells, compositions, and methods for treating liver diseases.

Claims

1. A composition comprising a preparation containing cultured pluripotent animal cells that are (i) positive for CD29, CD44, CD49b, CD49d, CD73, CD90, CD105, and CD 13;

and (ii) negative for CD14, CD34, HLA-DR, and CD45; and

a liver tissue.

2. The composition of claim 1, wherein the liver tissue is an isolated liver tissue.

3. The composition of claim 1, wherein the liver tissue is an injured liver tissue has been subjected to a hepatotoxic agent.

4. The composition of claim 1, wherein the pluripotent animal cells are obtained from the Wharton'"'"'s jelly of the umbilical cord of a first subject.

5. The composition of claim 4, wherein the first subject is a human.

6. The composition of claim 4, wherein the liver tissue is obtained from a second subject.

7. A method for obtaining hepatic progenitor cells, comprising

culturing the composition of claim 1 in a medium for a period of time;

and

collecting progenies of the cultured pluripotent animal cells to obtain hepatic progenitor cells,

wherein the pluripotent animal cells are obtained from the Wharton'"'"'s jelly of the umbilical cord of a first subject.

8. The method of claim 7, wherein the hepatic progenitor cells express one or more of genes selected from the group consisting of CK18, albumin, tryptophan 2,3-dioxygenase (TO), afetoprotein (AFP), CYP7A1, nanog, oct4, ckit, HGF, and MMP.

9. The method of claim 8, wherein the pluripotent animal cells are positive for HGF or MMP.

10. The method of claim 7, wherein the first subject is a human.

11. The method of claim 7, wherein the liver tissue is an injured liver tissue.